Evercore ISI Begins Coverage on Kenvue (NYSE:KVUE)

Evercore ISI assumed coverage on shares of Kenvue (NYSE:KVUE) in a report issued on Monday, MarketBeat Ratings reports. The brokerage issued an in-line rating and a $25.00 price target on the stock.

Other research analysts also recently issued reports about the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Citigroup reduced their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Finally, Barclays decreased their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $23.85.

Kenvue Stock Up 1.3 %

KVUE stock opened at $23.40 on Monday. The stock has a market cap of $44.72 billion, a P/E ratio of 44.15, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock’s fifty day simple moving average is $22.22 and its two-hundred day simple moving average is $22.45. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts expect that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Institutional Trading of Kenvue

Institutional investors and hedge funds have recently bought and sold shares of the company. Grove Bank & Trust grew its position in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Kenvue during the fourth quarter valued at $29,000. SRS Capital Advisors Inc. grew its position in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after buying an additional 571 shares in the last quarter. Fortitude Family Office LLC increased its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.